The UK-based contract research organization (CRO) RxCelerate opened a US office in Boston in late 2018. Earlier in the year, the company also acquired the specialist bioanalytical CRO Total Scientific.
Now, RxCelerate has announced its acquisition of Prosarix, a molecular modeling company that supports both protein engineering and in silico drug design projects.
“Following the acquisition of bioanalytical CRO Total Scientific and sector-focused back-office service provider The Cambridge Partnership during 2018, this new acquisition underlines our commitment to complete the jigsaw, so that our clients can access world-leading drug discovery capability under one roof,” said RxCelerate Founder and Chairman Dr. David Grainger in a press release.
Prosarix’s ProtoDiscovery platform for small molecule design and protein engineering has been in use since the company’s inception in 2006.
RxCelerate has not responded to a request for comment.